Published in Breast Cancer Res Treat on November 11, 2012
Cost trend analysis of initial cancer treatment in Taiwan. PLoS One (2014) 0.81
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. Indian J Med Paediatr Oncol (2016) 0.80
Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? Oncologist (2015) 0.78
Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer. Breast Cancer Res Treat (2017) 0.75
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol (2006) 1.81
Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med (2012) 1.69
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. Arch Surg (2010) 1.39
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol (2013) 1.30
Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom Med (2008) 1.27
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 1.23
Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat (2013) 1.21
Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep (2012) 1.17
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol (2008) 1.14
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer (2009) 1.14
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2010) 1.14
Participation in cancer clinical trials: why are patients not participating? Med Decis Making (2013) 1.10
Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control (2009) 1.08
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med (2013) 1.05
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat (2014) 1.05
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer (2012) 1.05
Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res (2006) 1.02
Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther (2008) 1.01
Primary ectopic breast cancer presenting as a vulvar mass. Clin Breast Cancer (2006) 1.01
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics (2014) 0.98
Adjuvant and preoperative therapy for localized gastric cancer. Gastrointest Cancer Res (2007) 0.97
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer (2011) 0.95
Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat (2012) 0.95
Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother (2007) 0.95
Successful treatment of anal gland adenocarcinoma with combined modality therapy. Gastrointest Cancer Res (2012) 0.90
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol (2011) 0.90
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat (2011) 0.90
Sleep quality and fatigue after a stress management intervention for women with early-stage breast cancer in southern Florida. Int J Behav Med (2014) 0.89
Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors. Gastrointest Cancer Res (2008) 0.88
Interferon-gamma suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbeta binding. Arterioscler Thromb Vasc Biol (2007) 0.86
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev (2011) 0.86
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. Med Oncol (2014) 0.86
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs (2013) 0.85
Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag (2008) 0.85
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther (2007) 0.84
Chemoprevention of breast cancer. Expert Rev Anticancer Ther (2008) 0.84
Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol (2010) 0.83
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) (2011) 0.83
Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer? Expert Opin Ther Targets (2012) 0.83
Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol (2012) 0.83
The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress. Free Radic Biol Med (2012) 0.82
Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells (2005) 0.82
Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? Breast Cancer Res Treat (2014) 0.81
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat (2014) 0.81
Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study. Breast Cancer Res Treat (2015) 0.79
Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) (2012) 0.79
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat (2010) 0.79
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer (2007) 0.78
Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosom Med (2016) 0.78
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer (2007) 0.78
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Med Oncol (2011) 0.78
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep (2012) 0.78
Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol (2004) 0.77
Gene expression profiling in breast cancer. Am J Transl Res (2013) 0.77
Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep (2012) 0.77
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.77
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat (2014) 0.76
A case of severe thrombotic thrombocytopenic purpura with concomitant Legionella pneumonia: review of pathogenesis and treatment. Am J Ther (2011) 0.76
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs (2014) 0.76
Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory. Am J Cancer Res (2011) 0.76
Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer. Cancer Biol Ther (2010) 0.75
Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standard. J Gastrointest Oncol (2011) 0.75
Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L. Immunol Res (2013) 0.75
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biol Ther (2008) 0.75
Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Int J Biol Markers (2013) 0.75
Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? Clin Adv Hematol Oncol (2008) 0.75
Introduction to special issue translational goals of neoadjuvant therapy. Breast Cancer Res Treat (2012) 0.75
Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro. Stem Cells Dev (2004) 0.75